
Opinion|Videos|October 31, 2024
Generalized Myasthenia Gravis Classification and Treatment Strategy
Key Takeaways
- gMG classification considers clinical presentation, antibody status, and disease severity to guide treatment strategies.
- The MGFA clinical classification system categorizes patients from Class I (ocular symptoms) to Class V (intubation required).
Panelists discuss how the classification of generalized myasthenia gravis (gMG) informs and guides treatment strategies for patients.
Advertisement
Video content above is prompted by the following:
- How do you classify gMG, and how does this guide your treatment strategy?
Advertisement
Related to this article

Interim phase 1b/2a data showed all patients treated with high- or low-dose BB-301 for oculopharyngeal muscular dystrophy met formal response criteria.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of neurology!

Although ocular signs in LEMS are typically mild and appear late, recognizing them alongside proximal weakness and autonomic symptoms can speed diagnosis and earlier detection of an associated lung cancer.

Shaida Khan, DO, associate professor of neurology at UT Southwestern Medical Center, reflected on a recent NeurologyLive Clinical Forum on generalized myasthenia gravis and discussed how FcRn and complement inhibitors are reshaping treatment algorithms for the disease.

The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with M. Scott Perry, MD. [LISTEN TIME: 15 minutes]
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Examining Trontinemab in Early Alzheimer Disease: The Phase 3 TRONTIER 1 and 2 Trials
2
Remibrutinib Phase 3 Results in RMS, Blood Pressure Variability Findings, and Updated Stroke Rehabilitation Guidelines
3
How MS Understanding Has Evolved: Activity, Impact, and Progression
4
Benitec Reports Positive Interim Results for BB-301 in Oculopharyngeal Muscular Dsytrophy
5


